Developing immunotherapies with Hu-NSG-MHC I/II DKO mice
29 May 2022
The NSG-MHC I/II DKO mouse model has the features of the severe combined immune deficiency mutation (scid), IL2 receptor gamma chain deficiency, MHC class I molecule deficiency (H2-K and D), and MHC class II molecule deficiency (IA). Due to the deficiency of murine MHC class I and class II molecules, this model demonstrates significantly delayed onset of graft-versus-host disease (GvHD) when transplanted with pre-characterized human PBMCs.
In this video, The Jackson Laboratory discusses using PBMC humanized NSG-MHC I/II DKO mice in preclinical research to develop and assess efficacy of human immuno-therapeutics.
About the company
The Jackson Laboratory
The Jackson Laboratory is a global leader in preclinical studies and has been driving therapeutic development breakthroughs for over 90 years. With the most innovative preclinical platforms including humanized mice, and services such as dose ranging, toxicity, and efficacy studies, JAX empowers drug developers and researchers worldwide.
Related products
Request Quote for All Products
JAX® Mice and Services
The Jackson LaboratoryTake advantage of our large inventories of common inbred strains and the convenience of having your breeding and drug efficacy needs met by the leading experts in mouse modeling.
